News

Results from preclinical studies show the PIG3 protein as a key player in LRRK2-mediated familial Parkinson’s disease. The findings were discussed in two presentations at the Society for Neuroscience (SfN) 2018 annual meeting in San Diego, California. Mutations in the LRRK2 gene — the leading genetic cause of Parkinson’s — account for…

Intec Pharma announced the complete enrollment of a Phase 3 clinical trial evaluating the safety and effectiveness of its Accordion Pill Carbidopa/Levodopa (AP-CD/LD) in easing motor fluctuations in people with advanced Parkinson’s disease. The investigative treatment will be compared to immediate release Sinemet, an approved combination of levodopa and carbidopa marketed…

Johns Hopkins researchers have identified a specific cell death pathway named Parthanatos — after Thanatos, the ancient Greek personification of death — that leads to the physical and intellectual degeneration associated with Parkinson’s disease. They also found that a protein called PARP-1 is a key mediator of cell death via Parthanatos, supporting the…